The dopamine receptor agonist ropinirole emerged as the top hit in a screen of induced motor neurons.
The 2019 budget ups this year’s spending by $425 million.
Neural-wave patterns could help clinicians guide electrodes for deep-brain stimulation.
Tau-laden neurons present a phospholipid “eat me” signal, bidding microglia to devour them alive.
Data from two independent cohorts suggest that the risk to the brain from high blood pressure and cardiovascular disease begins in a person’s 40s or before.
At AAIC, competitors vied for advantage, and discussion moved swiftly to the issue of assay standardization.
Greater lifetime estrogen exposure protects cognition, while hormone replacement therapy taken at menopause has no cognitive effects at all.
At AAIC, scientists said that alterations in how the aging female brain uses energy and metabolizes fat may leave APOE4 carriers particularly susceptible to tau pathology.
At AAIC, technology improves on pen-and-paper tests of early cognitive decline. Think learning Chinese, think smartphone burst, think digital clock.
A new PET tracer belies previous results from animal models and postmortem studies. Caveat emptor for trials of HDAC inhibitors?
Sensitive cognitive tests detect deficits in preclinical Alzheimer’s even before an amyloid scan reads positive. And CSF Aβ42 drops a decade before that—pushing research ever farther into the preclinical phase.
New data from gantenerumab and N3pG confirm that high-dose antibodies clear plaque dramatically, with manageable side effects. How will the aging brain respond?
A batch of new monoclonal antibodies against the C9ORF72 protein also revealed the protein lingers in presynapses.
A zinc-finger protein and a long noncoding RNA are now implicated in late-onset Alzheimer’s disease.
In early Parkinson’s disease, sparse areas on the retina correlate with dying dopaminergic neurons in the substantia nigra.
No filters selected